# A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin

> **NCT06257966** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Beijing Dongfang Biotech Co., Ltd.** · enrollment: 600 (actual)

## Conditions studied

- Type2 Diabetes Mellitus

## Interventions

- **DRUG:** Exendin-4 Fc fusion protein injection(1.2mg）
- **DRUG:** Exendin-4 Fc fusion protein injection（2.4mg）
- **DRUG:** Dulaglutide
- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT06257966
- **Lead sponsor:** Beijing Dongfang Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-07-17
- **Primary completion:** 2026-10-01
- **Final completion:** 2026-11-30
- **Target enrollment:** 600 (ACTUAL)
- **Last updated:** 2025-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06257966

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06257966, "A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06257966. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*